Stockscreener 앱 받기
78.43
0.65%
-0.51
시간 외 거래:
77.47
-0.96
-1.22%
전일 마감가:
$78.94
열려 있는:
$79.1
하루 거래량:
631.58K
Relative Volume:
1.63
시가총액:
$1.76B
수익:
$747.40M
순이익/손실:
$-12.60M
주가수익비율:
-102.03
EPS:
-0.7687
순현금흐름:
$105.18M
1주 성능:
-4.83%
1개월 성능:
-4.49%
6개월 성능:
+20.25%
1년 성능:
+41.47%
1일 변동 폭
$77.41
$80.28
1주일 범위
$77.41
$82.53
52주 변동 폭
$52.73
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(218) 634-3500
주소
210 MAIN STREET WEST, BAUDETTE, MN
ANIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
78.43 | 1.77B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
ZTS
Zoetis Inc
|
125.90 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.95 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Revenue per share of ANI Pharmaceuticals, Inc. – MUN:BSFA - TradingView — Track All Markets
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Globe and Mail
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Assessing ANI Pharmaceuticals (ANIP) Valuation After a Strong Yearly Share Price Rally - Yahoo Finance
ANI Pharma stock pullback tied to Cortrophin guidance uncertainty - Investing.com
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling - MarketBeat
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? - MSN
Will ANI Pharmaceuticals Inc. stock attract ESG investorsMarket Trend Summary & AI Powered Market Entry Ideas - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $133,652.80 in Stock - MarketBeat
ANI Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
VP Davis Sells 1,622 ($133.7K) Of ANI Pharmaceuticals Inc [ANIP] - TradingView — Track All Markets
How ANI Pharmaceuticals Inc. stock reacts to global recession fearsMarket Growth Review & Reliable Price Breakout Signals - DonanımHaber
Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Can ANI Pharmaceuticals Inc. stock rebound after recent weaknessQuarterly Trade Review & Daily Oversold Bounce Ideas - DonanımHaber
Is ANI Pharmaceuticals Inc. stock trading at a premium valuationWeekly Gains Summary & Weekly Watchlist for Hot Stocks - Улправда
Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Recap & Safe Capital Growth Tips - Улправда
ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum - Sahm
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Why ANI Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - Finviz
Is ANI Pharmaceuticals Stock Price Justified After 47% 2025 Rally? - Yahoo Finance
How Investors May Respond To ANI Pharmaceuticals (ANIP) Creating a Retina-Focused FutureVision Advisory Council - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Ranger Investment Management L.P. Reduces Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Implied volatility surging for ANI Pharmaceuticals stock options - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $32,928.00 in Stock - MarketBeat
ANI Pharmaceuticals Senior VP Meredith Cook Sells 400 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (ANIP) officer Meredith Cook sells 400 shares via 10b5-1 plan - Stock Titan
ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim - MSN
ANI Pharmaceuticals (ANIP): Assessing Valuation After a Strong Year and Recent Share Price Pullback - Sahm
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? - MSN
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Nasdaq
ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares - MSN
ANI Pharmaceuticals Director Sold $146K In Company Stock - Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock - MarketBeat
ANI Pharmaceuticals Director Sells 1,800 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates ANI Pharmaceuticals at Overweight With $100 Price Target - marketscreener.com
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed - MSN
ANI Pharmaceuticals (ANIP): Has the Recent Share Price Pullback Created a Valuation Opportunity? - Yahoo Finance
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by JPMorgan Chase & Co. - MarketBeat
Kennedy Capital Management LLC Reduces Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
The Bull Case For ANI Pharmaceuticals (ANIP) Could Change Following Governance Shake-Up And FutureVision Launch – Learn Why - Sahm
Is ANI Pharmaceuticals Inc. (BSFA) stock a buy for dividend portfoliosPortfolio Performance Report & Low Drawdown Investment Strategies - Newser
ANI Pharmaceuticals (ANIP): Valuation Check After Governance Shake-Up and New Rare Disease Strategy Moves - Sahm
Sio Capital Management LLC Buys 25,625 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ani Pharmaceuticals Inc 주식 (ANIP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Dec 12 '25 |
Sale |
82.32 |
400 |
32,928 |
74,874 |
| TANNENBAUM RENEE P | Director |
Dec 05 '25 |
Sale |
81.15 |
1,800 |
146,070 |
25,157 |
2.19%
0.08%
자본화:
|
볼륨(24시간):